Combining Afatinib and Cetuximab synergistically increases their cytotoxicity for EGFR T790M-harboring cells

阿法替尼和西妥昔单抗的组合可协同增加其对携带 EGFR T790M 细胞的细胞毒性

• 批准号: 24591184
• 负责人: MAEMODNO MAKOTO
• 金额: $ 3.41万
• 依托单位: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24591184/
• 关键词: 癌; 非小細胞肺癌; 治療法; 肺癌; EGFR-TKI; EGFR

项目成果

Variability of epidermal growth factor receptor (EGFR) mutations in serum during erlotinib therapy and its clinical implications: exploratory analysis of a phase II study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring

厄洛替尼治疗期间血清中表皮生长因子受体（EGFR）突变的变异性及其临床意义：厄洛替尼治疗晚期非小细胞肺癌（NSCLC）患者的 II 期研究的探索性分析

• 发表时间: 2013
• 作者: Makoto Maemondo;Makoto Nishio;Noboru Yamamoto;Kenichi Chikamori;Nobuyuki Katakami;Toyoaki Hida;Takashi Seto;Hiroshige Yoshioka;Toshiyuki Kozuki;Norihisa Ohishi;Tomohide Tamura
• 通讯作者: Tomohide Tamura

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

• DOI: 10.1016/j.lungcan.2013.07.003
• 发表时间: 2013-10-01
• 期刊: LUNG CANCER
• 影响因子: 5.3
• 作者: Goto, Koichi;Nishio, Makoto;Tamura, Tomohide
• 通讯作者: Tamura, Tomohide

Phase II study of combination therapy with S-1 and irinotecan in EGFR-mutated non-small cell lung cancer (NSCLC) resistant to both platinum-based chemotherapy and EGFR-TKI: NJLCG0804

S-1 和伊立替康联合治疗对铂类化疗和 EGFR-TKI 耐药的 EGFR 突变非小细胞肺癌 (NSCLC) 的 II 期研究：NJLCG0804

• 发表时间: 2013
• 作者: Maemondo M;Sugawara S;Harada T;Fukumoto S;Inoue A;Ishimoto O;Matsubara N;Harada M;Kobayashi K;Nukiwa T
• 通讯作者: Nukiwa T

One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC) North Japan Lung Cancer Group 0803

高选择性 ALK 抑制剂 CH5424802/RO5424802 在 ALK 重排的晚期非小细胞肺癌 (NSCLC) 北日本肺癌组 0803 中的 I/II 期研究的一年随访

• 发表时间: 2013
• 作者: Akira Inoue;Makoto Nishio;Katsuyuki Kiura;Takashi Seto;Kazuhiko Nakagawa;Makoto Maemondo;Toyoaki Hida;Hiroshige Yoshioka;Masao Harada;Yuichiro Ohe;Naoyuki Nogami;Haruyasu Murakami;Kengo Takeuchi;Kazue Kikuchi;Takashi Asakawa;Shumpei Yokoyam
• 通讯作者: Shumpei Yokoyam

Runx1 deficiency in CD4+ T cells causes fatal autoimmune inflammatory lung disease due to spontaneous hyperactivation of cells.

CD4 T 细胞中的 Runx1 缺陷会因细胞自发过度激活而导致致命的自身免疫性炎症性肺病。

• DOI: 10.4049/jimmunol.1102991
• 发表时间: 2012
• 期刊: J Immunol.
• 作者: Wong WF;Tazawa R;（15名略）Nakata K;Takai T;Satake M.
• 通讯作者: Satake M.